Retinoic Acid Inhibits Tumor-Associated Mesenchymal Stromal Cell Transformation in Melanoma

Bone marrow mesenchymal stem/stromal cells (BMSCs) can be transformed into tumor-associated MSCs (TA-MSCs) within the tumor microenvironment to facilitate tumor progression. However, the underline mechanism and potential therapeutic strategy remain unclear. Here, we explored that interleukin 17 (IL-17) cooperating with IFN gamma transforms BMSCs into TA-MSCs, which promotes tumor progression by recruiting macrophages/monocytes and myeloid-derived suppressor cells (MDSCs) in murine melanoma. IL-17 and IFN gamma transformed TA-MSCs have high expression levels of myelocyte-recruiting chemokines (CCL2, CCL5, CCL7, and CCL20) mediated by activated NF-kappa B signaling pathway. Furthermore, retinoic acid inhibits NF-kappa B signaling, decreases chemokine expression, and suppresses the tumor-promoting function of transformed TA-MSCs by prohibiting the recruitment of macrophages/monocytes and MDSCs in the tumor microenvironment. Overall, our findings demonstrate that IL-17 collaborating with IFN gamma to induce TA-MSC transformation, which can be targeted by RA for melanoma treatment.

Automated summary

This study found that interleukin 17 (IL-17) cooperating with interferon gamma can transform bone marrow mesenchymal stem/stromal cells (BMSCs) into tumor-associated MSCs (TA-MSCs), promoting tumor progression. Retinoic acid inhibits the NF-κB signaling pathway to regulate the function of TA-MSCs and inhibit tumor growth.